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Abstract 
We investigate the epistemological consequences of a positive polymerase chain reaction SARS-CoV 
test for two relevant hypotheses: (i) V is the hypothesis that an individual has been infected with 
SARS-CoV-2; (ii) C is the hypothesis that SARS-CoV-2 is the cause of flu-like symptoms in a given 
patient. We ask two fundamental epistemological questions regarding each hypothesis: First, how 
much confirmation does a positive test lend to each hypothesis? Second, how much evidence does a 
positive test provide for each hypothesis against its negation? We respond to each question within a 
formal Bayesian framework. We construe degree of confirmation as the difference between the 
posterior probability of the hypothesis and its prior, and the strength of evidence for a hypothesis 
against its alternative in terms of their likelihood ratio. We find that test specificity – and coinfection 
probabilities when making inferences about C – were key determinants of confirmation and 
evidence. Tests with <87% specificity could not provide strong evidence (likelihood ratio >8) for V 
against ¬V regardless of sensitivity. Accordingly, low specificity tests could not provide strong 
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evidence in favor of C in all plausible scenarios modeled. We also show how a positive influenza A 
test disconfirms C and provides weak evidence against C in dependence on the probability that the 
patient is influenza A infected given that her symptoms are not caused by SARS-CoV-2. Our analysis 
points out some caveats that should be considered when attributing symptoms or death of a 
positively tested patient to SARS-CoV-2. 
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Introduction 
Currently, the world is a state of emergency caused by the new virus called severe acute respiratory 
syndrome-corona virus-2, or short SARS-CoV-2. COVID-19 (coronavirus disease 2019) is the term 
used to describe the disease symptoms caused by the SARS-CoV-2. Symptoms of COVID-19 are 
typically flu-like symptoms such as fever and cough and in severe cases pneumonia, which however 
predominantly occurs in frail patients with other comorbidities. In general, SARS-CoV-2 appears to 
cause similar symptoms as other coronaviruses or influenza strains (Guan et al. 2020; Shi et al. 2020).  
To prevent the virus from spreading and causing symptoms and deaths, policy makers at the helm of  
affairs had taken dramatic measures which included the closure of kindergartens, schools and 
universities, restaurants, museums and shops, prohibition of gatherings, cancellation of public events 
and the prohibition to leave the house without good reason. These measures were justified under 
the premise that SARS-CoV-2 is extremely virulent. However, the validity of this premise itself is 
rarely investigated. In particular, which data justify this premise? It appears that the positive testing 
of patients and its reporting in the media play a central role in sustaining the belief in a high virulence 
of SARS-CoV-2 and the notion of a pandemic. Our goal here is therefore to conduct a critical analysis 
of the SARS-CoV-2 testing and the conclusions that can be drawn from it based on a Bayesian 
account of evidence and confirmation. 
Evidence, confirmation, and diagnostic testing 
A comprehensive understanding of scientific hypotheses requires an understanding of scientific 
inference, broadly construed. However, several epistemological issues need to be distinguished in 
order to appreciate the proper relationship between the tenability of scientific hypotheses and 
inference. We will discuss the significance of these issues/questions by borrowing an insight from 
Richard Royall (Royall 1997; Royall 2004). Our approach provides a unified Bayesian response to 
three questions posed by Royall. 
Consider two hypotheses: V, stating that a patient is infected with the SARS-CoV-2, and ¬V, its denial. 
Assume that a SARS-CoV-2 test comes out positive. Based on this simple scenario, one could pose at 
least three types of question that underline the epistemological issues at stake, following an insight 
from Royall (1997): 
(i) Given the positive test result, what should we believe about V and to what degree?  
(ii) Does the positive test result provide strong evidence for V against its alternative ¬V? 
(iii)  Given the positive test result, what should we do? 
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We call the first question the belief or confirmation question, the second the evidence question and 
the third the decision question. These three questions are pre-theoretical and statistical paradigm-
neutral; yet they require some statistical/probabilistic tools for their articulation. Here, we will 
confine ourselves to the first two questions and just briefly touch upon the decision question in the 
Discussion section. 
We have developed two distinct accounts to answer the first two types of questions (Bandyopadhyay 
and Brittan 2006; Bandyopadhyay et al. 2016). The first is an account of belief/confirmation, the 
second of evidence. Our two accounts of belief/confirmation and evidence naturally fulfill the need 
to have both notions of degrees-of-belief and degrees-of-support pointed out by Hawthorne (2005), 
which not only avoids the old evidence problem but also resolves a number of other philosophical 
paradoxes (Bandyopadhyay et al. 2016). 
For Bayesians, degrees of belief need to be fine-grained (Ramsey 1926). A satisfactory Bayesian 
account of confirmation, according to us, should be able to capture this notion of degree of belief. In 
formal terms:  
 D confirms H to a greater degree if and only if P(H|D) > P(H),  (1) 
where D denotes the data and H the hypothesis. Confirmation becomes strong or weak depending 
on how great the difference is between the posterior probability, P(H|D), and the prior probability of 
the hypothesis, P(H). P(H|D) represents an agent’s degree of belief in the hypothesis after the data 
are accumulated. P(H) stands for an agent’s degree of belief in the hypothesis before the data for the 
hypothesis have been acquired. 
While the account of confirmation is concerned with belief in a single hypothesis, our account of 
evidence compares the merits of two simple statistical hypotheses, H1 and H2 (or ¬H1) relative to 
the data D, some auxiliaries, and background information1. Bayesians use the Bayes factor to make 
this comparison, while others use the likelihood ratio (LR) or other functions designed to measure 
evidence. For simple statistical hypotheses/models with no free parameters2, as is the case in 
diagnostic testing that is treated here, the Bayes factor and the LR are identical, and capture the bare 
essentials of an account of evidence without any appeal to prior probability. The LR in favor of H1 
over H2 is 
LR=P(D|H1)/ P(D|H2)  (2) 
                                                          
1
 The dependence on auxiliaries and background information will not be explicitly stated in the equations. 
2
 See Bandyopadhyay et al. (1996) for a general model selection case when models have adjustable parameters.  
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The data D constitute evidence for H1 against H2 if and only if their LR is greater than one. Note that, 
if 1< LR ≲ 8, then D is often said to provide weak to moderate evidence for H1 against H2, while 
when LR ≳ 8, D provides strong evidence (Kass and Raftery 1995; Bandyopadhyay et al. 2016). This is 
also the cut-off and characterization of evidence we use in this work. 
Sensitivity and specificity 
In the following, we assume that testing for SARS-CoV-2 is based on reverse transcriptase –
quantitative polymerase chain reaction (RT-qPCR), a biomedical testing procedure that is routinely 
applied for detecting and quantifying RNA. Such tests are able to detect very few numbers of nucleic 
acid molecules – in this case RNA – by amplifying a target nucleic acid sequence several million fold. 
Because RNA cannot serve as a template for PCR, the RNA template is first reversely transcribed (RT) 
into complementary DNA (cDNA)3 which is then exponentially amplified in a PCR over many cycles 
(Bustin 2000). In quantitative (also called real time) PCR one can calculate the number of DNA 
molecules of the amplified sequence that were initially present in the sample (Kubista et al. 2006, 
96). However, for such a calculation to be reliable several operating standards should be followed 
closely, else sensitivity (true positive rate) and specificity (true negative rate) may be compromised 
(Raymaekers et al. 2009). 
Upon the spread of the SARS-CoV-2 in Wuhan, China, new RT-qPCR tests have been rapidly 
developed. For example, Corman et al. created a test based on the closely related SARS-CoV from 
2003 and got their paper published in January 2020 only two days after submission (Corman et al. 
2020). Nowadays, a multitude of more or less defined commercial and laboratory "in house" tests 
are used, often without mandatory guidelines and adequate validation. While some of these tests 
have shown 100% specificity in independent validation studies (Nalla et al. 2020), others have been 
found to yield a significant percentage of false-negative results. For example, an early validation 
study of Chinese SARS-CoV-2 RT-qPCR tests revealed a false positive rate of almost 50% or higher 
(Zhuang et al. 2020) – however, the study was retracted for unknown reasons soon after ahead-of-
print publication. In a German inter-laboratory validation study (“Ringversuch”) of many 
commercially available and in-house RT-qPCR tests, a total of 67 out of 983 SARS-CoV-2-negative 
samples containing the human coronavirus HCoV 229E were classified as “positive”, yielding an 
average false-positive rate of 6.8% (Zeichhardt and Kammel 2020). Another German laboratory found 
some commercial primers and probes to be contaminated with nucleotides, resulting in up to 7.3% 
false positive results from SARS-CoV-2-negative human throat swabs and up to 17% false positive 
results from swabs taken from cattle (Wernike et al. 2020). Finally, the test used by the US Center for 
                                                          
3
 To provide RT enzymes a starting point for synthesis, specific primers flanking the RNA sequence to be 
amplified are used. Their choice is crucial for estimating the RNA copy number (Bustin 2000). 
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Disease Control appears to have specificity problems, as 3/10 reference samples classified as positive 
by RT-qPCR did not contain SARS-CoV-2 (Lee 2020).   
SARS-CoV-2 RT-qPCR tests may also have problems with sensitivity in clinical routine application. The 
reason is that sensitivity depends on both the site from which a sample is obtained and the time 
relative to symptom onset (Sethuraman et al. 2020). Xie et al. (2020) reported on five patients 
presenting with flu-like symptoms and radiological diagnosis of COVID-19 pneumonia, but negative 
RT-qPCR test results; in these patients it took multiple re-tests to obtain a positive SARS-CoV-2 
detection. Similar findings were reported by Li et al. (2020) who conducted multiple tests on the 
same patients diagnosed with COVID-19 but observed highly variable results. Here, 13.5% (48/355) of 
symptomatic patients who had initially tested negative were SARS-CoV-2 positive at the second test, 
and 18 patients had a positive test after two consecutive negative ones. In particular tests based on 
the frequently taken nasopharyngeal swabs appear to be not very sensitive (Xiaojing Wu et al. 2020). 
In a Chinese study on patients with confirmed COVID-19, sensitivity was only 32% (126/398) for 
pharyngeal swabs and 63% (5/8) for nasal swabs compared to 93% (14/15) for bronchoalveolar 
lavage fluid (Wang et al. 2020). This is consistent with the percentage of positive test results from 
nasopharyngeal swabs of COVID-19 patients by Guo et al. (2020) (51.9%) and Liu et al. (2020).  
In summary we conclude that both the sensitivity and specificity of SARS-CoV-2 tests are context-
dependent4. We therefore investigate how test inferences depend on various sensitivities and 
specificities for which we adopt specificity ≥80% and sensitivity ≥30% as realistic ranges. 
The base rate 
Due to the novelty of the SARS-CoV-2 and the fact that most infections remain undetected the base 
rates are still very uncertain. The base rate is also population-specific and space-time-dependent. In 
Table 1 we have compiled several infection rate estimates from various contexts. While taking these 
as base rate estimates assumes perfect tests, we are not so much interested in the exact values, but 
in a crude realistic range for our modelling study. We see that in asymptomatic persons, most studies 
support a base rate between 0 and 5%, while high-risk populations range somewhere between 5% 
and 20% (counting the 37.9% obtained by Folgueira et al. (2020) as an outlier). Therefore, realistic 
base rates are somewhere in the range 0-20% which we account for by plotting base rate on a log 
scale in order to better visualize test inferences for low base rates. 
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 Context-dependence of test performances is not restricted to the new SARS-CoV-2 tests. The reason is that 
such tests are not experiments within closed systems, but are conducted on open systems that are highly 
responsive to their environment or the given context (Klement and Bandyopadhyay 2019).   
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Population Time Specimen Infection rate Reference 
161 hospitalized 
children in Wuhan, 
China 
December 1, 
2019 – 
January 16 
Nasopharyngeal 
swab, sputum or 
bronchoalveolar 
lavage fluid 
1.2% Jian et al. (2020) 
151 close 
household contacts 
of COVID-19 
patients in Taiwan 
January 15 – 
March 18, 
2020 
NA 4.6% Cheng et al. 
(2020) 
32 suspected SARS- 
CoV-2 cases and 
337 people 
repatriated from 
China 
January – 
February, 
2020 
NA 0% Colson et al. 
(2020) 
9199 inhabitants of 
Iceland with high 
risk of infection 
January 31 – 
March 31, 
2020 
Nasopharyngeal 
and 
oropharyngeal 
swabs 
13.3% Gudbjartsson et 
al. (2020) 
1911 symptomatic 
health care 
workers from 
Madrid, Spain 
February 24 –
April 30 
Nasopharyngeal 
swab 
11.1% a Suárez-García 
(2020) 
2085 hospital 
healthcare workers 
in Madrid, Spain 
March 1 – 29 , 
2020 
Nasopharyngeal 
and 
oropharyngeal 
swabs 
37.9% a Folgueira et al. 
(2020) 
131 patients with 
mild influenza-like 
illness from a Los 
Angeles medical 
center, USA 
March 12–16, 
2020 
Nasopharyngeal 
swabs 
5.3% Spellberg et al. 
(2020) 
783 asymptomatic 
repatriation 
passengers arriving 
in Greece 
March 20–25, 
2020 
Oropharyngeal 
swabs 
3.6–6.3% Lytras et al. 
(2020) 
210 asymptomatic 
pregnant women 
from New York, 
USA 
March 22 – 
April 4, 2020 
Nasopharyngeal 
swabs 
13.7% Sutton et al. 
(2020) 
400 asymptomatic 
health care 
workers in London 
hospital, UK 
March 23–
April 26, 2020 
Nasal swabs 1.1%-7.1% 
(decreasing every 
week) 
Treibel et al. 
(2020) 
919 randomly 
chosen individuals 
from Gangelt, 
Germany 
March 31–
April 6, 2020 
Pharyngeal swabs 3.59% Streeck et al. 
(2020) 
2283 randomly March 31 – Nasopharyngeal 0.6% Gudbjartsson et 
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chosen 
asymptomatic 
inhabitants of 
Iceland 
April 4, 2020 and 
oropharyngeal 
swabs 
al. (2020) 
381 hospitalized 
patients in Wuhan, 
China  
April 3–15, 
2020 
Nasopharyngeal 
swabs 
0.3% Wu et al. (2020) 
1021 
asymptomatic 
resuming patients 
in Wuhan, China 
April 3–15, 
2020 
Nasopharyngeal 
swabs 
0% Wu et al. (2020) 
Table 1: SARS-CoV-2 infection rates based on positive RT-qPCR test results from various settings in 
chronological order. We do not provide uncertainties on these estimates stemming from binomial 
statistics or test imperfection, since we are only interested in a crude range that the infection rates 
occupy.  aSome persons were tested more than once. 
 
 
The two questions revisited 
Basic inferences from a positive SARS-CoV-2 test 
Let us now assume that a person5 has been tested positive for SARS-CoV-2. We are interested in the 
following hypotheses: 
V: The person is infected with the SARS-CoV-2 
¬V: The person is not infected with the SARS-CoV-2 
Given the positive test result, what should we believe about the infection status of the person and to 
which degree? This question can be answered by calculating the posterior probability of V and 
comparing it to its prior probability.  
Given T, the positive test result, we can derive the posterior probability of V from Bayes’ theorem: 
P(V|T) = [P(T|V) × P(V)]/P(T)  (3) 
P(T) = P(T|V)×P(V) + P(T|¬V )×P(¬V)  (4) 
The left panel of Figure 1 shows the degree of confirmation of the hypothesis that the person is 
infected as a function of the base rate plotted on a log scale and five different assumptions for test 
sensitivity and specificity. Even for tests with 90% sensitivity and 95% specificity, the base rate would 
                                                          
5
 It does not necessarily have to be a patient with symptoms. 
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have to exceed 5.6% in order to raise our degrees of belief in V to more than 50%, while for tests 
with only 30% sensitivity and 80% specificity, a base rate >40% would be required. 
The right panel of Figure 1 shows the LR as a function of the test sensitivity for two assumed test 
specificities (=1-P(T|¬V)). For 80% specificity, one would not be justified to speak of a positive test 
result as providing strong evidence in favor of V, regardless of test sensitivity; more generally, this 
holds for any specificity falling below 87%. If test specificity is 95%, however, evidence for V would 
become strong for sensitivity >40%.  
 
COVID-19 and a positive SARS-CoV-2 test 
Imagine now a patient presenting with flu-like symptoms. Borghetti et al. (2020) have pointed out 
that patients being tested positive for SARS-CoV-2 could have co-infection with other pathogens, and 
listed several other viruses and bacteria that are able to cause symptoms similar to COVID-196. By 
now, several case reports (Borghetti et al. 2020; Cuadrado-Payán et al. 2020; Xiaojing Wu et al. 2020) 
and cohort studies (Jian et al. 2020; Kim et al. 2020; Lin et al. 2020) have revealed that co-infections 
between SARS-CoV-2 and other respiratory pathogens occur. Being aware of the fact, we therefore 
pose the following hypothesis: 
C: SARS-CoV-2 infection has caused the flu-like symptoms of the patient.7 
Implicit in this notion of causation is a presupposition that there exists at least one biological 
mechanism explaining how the virus can cause flu-like symptoms (Russo and Williamson 2007). This 
we take as our background knowledge that we do not explicitly state in the following equations. 
Given that COVID-19 has many symptoms in common with other viruses or common hospital 
bacteria, the negation of C could be conceived as the catch-all hypothesis for all these other possible 
causes: 
¬C: A pathogen other than SARS-CoV-2 has caused the flu-like symptoms of the patient. 
Therefore:  
¬C &V: SARS-CoV-2 infection is associated with but has not caused the symptoms of the patient. 8 
                                                          
6
 Among them are adenovirus, bocavirus, other coronaviruses, influenza viruses, rhinovirus or the bacteria 
Chlamydophila pneumoniae and Mycoplasma pneumoniae. 
7
 This is what some media reports implicitly assume to be true given a positive test. 
8
 In principle, we can let ¬C include the case that both SARS-CoV-2 and another pathogen cause the symptoms 
together, so that ¬C &V means “SARS-CoV-2 infection is associated with but has not solely caused the 
symptoms of the patient”. For simplicity, however, we continue by assuming the mono-causal scenario.  
10 
 
Now imagine a SARS-CoV-2 test is conducted and turns out positive. We can then ask to what degree 
the positive test result confirms hypothesis C. To this end, we construct the simple Bayesian network 
model depicted in Figure 2. The SARS-CoV-2 test assesses the truth of the hypothesis V, that the 
patient has the SARS-CoV-2 infection. As above, T stands for a positive test result. We conceive of V 
as a testable consequence of the hypothesis C; the truth of C is both a necessary and sufficient 
condition for the truth of V, because if C is true for a given patient it deductively follows that he/she 
must be infected with SARS-CoV-2. From this it follows that 
P(V|C) ≡ p = 1 > P(V|¬C)≡q  (5) 
P(C|¬V) = P(¬V|C) = 0    (6) 
P(T|C) = P(T|V) = sens    (7) 
To calculate the degree of confirmation given to C by a positive test report, we need to calculate 
P(C|T) = P(T|C) × P(C)/P(T) = 
P(T|C) P(C)
P(T|C) P(C)+P(T|¬C)P(¬C)
 (8)  
Defining c≡P(C), equation (8) becomes 
P(C|T) =
c
c+(1-c) P(T|¬C)
P(T|C)
 (9)  
To calculate the LR in the denominator of Equation (9) in terms of sensitivity and specificity, we re-
express the likelihood P(T|¬C) using the definition of conditional probability:       
P(T|¬C)=
P(T&¬C)
P(¬C)
 (10) 
Furthermore, according to the law of total probability (Pearl et al. 2016): 
P(T&¬C) = P(T&¬C&V) + P(T&¬C&¬V)  (11) 
We apply the product rules (Pearl et al. 2016) for the Bayesian network structure shown in Figure 2 
to calculate the total probabilities in Equation (11): 
P(T&¬C) = P(¬C) P(V|¬C) P(T|V) + P(¬C) P(¬V|¬C) P(T|¬V)   (12), 
By inserting Equation (12) into (10), we obtain  
P(T|¬C) = P(V|¬C) P(T|V) + P(¬V|¬C) P(T|¬V) (13), 
or, using the notations given in Figure 2: 
P(T|¬C) = q∙sens + (1-q)(1-spec)  (14) 
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We define the LR≡x and use Equations (7) and (14): 
x=
P(T|¬C)
P(T|C)
 =
q∙sens + (1-q)(1-spec)  
sens
 (15) 
Inserting (15) into (9) we get 
P(C|T) =
c
c+(1-c)x
  (16) 
Note that q≡P(V|¬C) in Equation (15) is the proportion among symptomatic cases not caused by 
SARS-CoV-2 which in addition to the symptom-causing pathogen carry the SARS-CoV-2. To obtain a 
reference point and upper limit for the magnitude of q, we therefore look at percentages of 
symptomatic patients with confirmed non-SARS-CoV-2 respiratory pathogen infection who 
additionally were tested positive for SARS-CoV-2. Such co-infection rates were found to vary from 
0/3380 in French patients tested since January 1 2020 (Colson et al. 2020) to 2/239 (0.8%) in Chinese 
children (Jian et al. 2020), 6/186 (3.2%) in Chinese adults (Lin et al. 2020) and 24/318 (7.5%) in 
Californian patients (Kim et al. 2020). Based on these data, we set an upper limit of q at 10%. 
In Figure 3 we plot the posterior P(C|T) against the prior probability P(C), adopting four different 
values for q: 0.5%, 2.5%, 5% and 10%. It can be seen that the confirmation we gain in the hypothesis 
C depends on its prior, the value for q and more on the specificity of the test than its sensitivity.  As q 
increases, the confirmation of C provided by a positive test result becomes weaker and less 
dependent on the test performance, in particular specificity. However, even in the scenario where 
10% of patients having symptoms not caused by SARS-CoV-2 are co-infected with SARS-CoV-2, a 
positive test would raise our degrees of belief in C to more than 50% if the prior probability c would 
exceed 29%. This may be a reasonable assumption during the height of the COVID-19 epidemic in a 
given country. 
In Figure 4 we have plotted the evidence provided by a positive test result for the hypothesis C 
against ¬C as a function of the test sensitivity for different fixed values of specificity and q. Note that 
in the depicted situations a positive test always constitutes evidence for C (likelihood ratio >1). This is 
consistent with the theorem that data constitute evidence for a hypothesis against its mutually 
exclusive and jointly exhaustive alternative if and only if the data confirm the hypothesis to a certain 
degree (Bandyopadhyay et al. 2016). Figure 4 shows that the evidence for C against ¬C is moderate 
to weak if test specificity is only 80%, even for 100% sensitive tests and very low q. For q=10%, this is 
also the case for highly specific (95%) tests. In scenarios with small probability of co-infection with 
SARS-CoV-2 (q=0.5%-5%) a positive test is able to provide strong evidence for C. Note however, that 
even for q=0.5%, the evidence for C against ¬C is not strong if sensitivity ranges below 40%; such low 
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sensitivity may be characteristic of RT-qPCR tests on pharyngeal swabs (Wang et al. 2020), so that 
tests using these specimen may generally be considered to allow no strong evidential inferences. 
 
COVID-19 and a positive test for influenza A 
Influenza A is one of the dominating respiratory viruses responsible for causing flu-like symptoms 
(Nickbakhsh et al. 2019). Coinfection of influenza A and SARS-CoV-2 has been documented 
(Cuadrado-Payán et al. 2020; Kim et al. 2020; Nowak et al. 2020; Xiaojing Wu et al. 2020). Imagine 
now that instead of a SARS-CoV-2 test, a test for influenza A has been performed in a patient with 
flu-like symptoms and came out positive. How does this affect an agent’s degree of belief in C and 
the evidence for C against its alternative? Using a model with the same structure as Figure 2 and 
similar notation as above, let T’ denote the positive test result (now for influenza A) and V’ the 
hypothesis that an influenza A infection is present. However, now we do not have a deductive 
relationship between C and V’ as was the case in the SARS-CoV-2 test example. Instead, V’ can be 
conceived as a testable consequence of C in the sense that P(V’|C) < P(V’|¬C).9 Let us define p′ ≡
 P(V’|C) and q′ ≡ P(V’|¬C). We assume q’>p’ because if C is true, it follows deductively that the 
patient must have SARS-CoV-2, so that p’ is the probability of a co-infection of SARS-CoV-2 with 
influenza A which appears to be ≈1% (Kim et al. 2020). In contrast, if ¬C is true, the symptoms are 
caused by a pathogen other than SARS-CoV-2, so q’ represents the sum of (i) the probability of a 
single influenza A infection plus (ii) the probability of co-infection of a non-SARS-CoV-2 pathogen 
with influenza A plus (iii) the probability of SARS-CoV-2 infection not causing the symptoms with 
influenza A causing the symptoms. The prevalence of influenza A infection among symptomatic 
patients testing negative for SARS-CoV-2 ranges from 10/845 (1.2%) (Nowak et al. 2020) over 
29/1101 (2.6%) (Kim et al. 2020) to 794/3380 (23.5%) (Colson et al. 2020). In these patients, because 
SARS-CoV-2 was not detected, we assume that ¬C was true. We also neglect any imperfections of the 
influenza A tests so that these fractions give us a crude lower limit for realistic estimates of q’ and 
show that the assumption q’>p’ is justified. Accordingly, we set p’=1% and vary q’ from 1.2% to 25%. 
The LR for the case of a positive influenza A test is 
x'=
P(T'|¬C)
P(T'|C)
  (17) 
                                                          
9
 We thereby apply a similar definition of the testable consequence as Bovens & Hartmann (2003)in their chapter 
on confirmation (page 90), the difference being that the probability of the consequence given that the hypothesis 
is false is greater than the probability of the consequence given that the hypothesis is true in our case, while it is 
the other way around in Bovens & Hartmann (2003). 
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The numerator in the LR can be re-formulated analogous to Equation (14). A similar derivation of the 
denominator gives 
P(T'|C)=
P(T'&C)
P(C)
=  
P(T'&C&V') + P(T'&C&¬V')
P(C)
=  P(V'|C) P(T'|V') + P(¬V'|C) P(T'|¬V')   (18) 
Using q’>p’, we thus obtain 
 
x' =
q'∙sens'+(1-q')(1-spec')
p'∙sens'+(1-p')(1-spec')
=
(sens'+spec'-1)q'+1-spec'
(sens'+spec'-1)p'+1-spec'
>1  (19) 
Hereby, sens’ and spec’ denote the sensitivity and specificity, respectively, of the influenza A test. 
These are better known than for the new SARS-CoV-2 test. We adopt the values derived by López 
Roa et al. (2011) for the influenza A RT-qPCR test which were obtained by comparison to 
conventional cell culture as the gold standard. These are sens’=95.6%, spec’=82.3%. Figure 5 plots 
the disconfirmation of C constituted by a positive influenza A test for five different values of q’ (left 
panel) as well as the evidence for ¬C against C as a function of q’ (right panel). Two results can be 
read off the graph: First, the smaller the chance of having co-infection with influenza A given that the 
symptoms are in fact caused by SARS-CoV-2, the stronger a positive influenza A test disconfirms the 
hypothesis C. Second, for all assumed values of q’, a positive test for influenza A would only 
constitute weak evidence for the hypothesis that the symptoms are caused by a pathogen other than 
SARS-CoV-2 (¬C) against C. 
 
VI. Discussion 
We here provided a critical investigation of the inferences that can be drawn from a positive SARS-
CoV-2 RT-qPCR test result for two main hypotheses: One is that a patient is infected with SARS-CoV-2 
(hypothesis V), the second that the flu-like symptoms of a patient are caused by this virus (C) and not 
any other pathogen (¬C). The two epistemological questions we posed are: Given a positive SARS-
CoV-2 test result (i) what should we believe about each hypothesis to what degree? (ii) What is the 
evidence for each hypothesis compared to its negation? 
We found that even for tests with 90% sensitivity and 95% specificity, the base rate would have to 
exceed 5.6% in order to raise our degrees of believe in V to more than 50%, while for tests with only 
30% sensitivity and 80% specificity, a base rate >40% would be required. Since base rates >40% are 
probably unrealistic (Table 1), but sensitivity around 30% has been reported for pharyngeal swabs 
(Wang et al. 2020), tests based on pharyngeal swab specimen would not convince a rational agent 
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that the tested person is infected with SARS-CoV-2. In addition, if the test would only have 80% 
specificity, positive tests cannot provide strong evidence (LR>8) in favor of V against ¬V (Figure 1, 
right panel). Qualitatively, the same result was obtained regarding hypothesis C (Figure 4). Thus, 
sample handling and contamination that might compromise specificity become crucial. 
The degree of confirmation for C was found to highly depend on the test specificity and in addition 
on the probability that a patient has asymptomatic SARS-CoV-2 coinfection when in fact his or her 
symptoms are caused by another pathogen. If this probability (that we denoted as q) is low, the 
degree of confirmation becomes high, and vice versa, ceteris paribus. 
Finally, we showed that a positive influenza A test would disconfirm C to a degree depending on the 
probability that the patient has influenza A infection given that his or her symptoms are not caused 
by SARS-CoV-2. As this probability, denoted q’, increases, the degree of disconfirmation also 
increases, ceteris paribus. However, a positive influenza A test provides only weak evidence against C 
for the realistic ranges of q’ considered. This is mainly because (i) we adopted a realistic assumption 
about the prevalence of influenza A infections that, despite being a very frequent pathogen causing 
flu-like symptoms, is less than about 25%, and (ii) because the test specificity for influenza A was only 
82.3%.   
Our analysis points out that one should be careful in ascribing the symptoms or death of a positively 
tested patient to COVID-19, if the possibility exists that the disease has been caused by another 
pathogen. To rule out the second possibility, one would have to test for all other possible symptom 
causes, which in practice is rarely attempted, and complicated by the fact that such tests are also not 
100% sensitive. 
Since COVID-19 is a novel disease and most tests used in practice have not been adequately 
validated, there are still many uncertainties associated with basic statistical quantities that we used 
in our modeling. We tried to account for these uncertainties by assuming several plausible values for 
the variables in our modeling. Yet, these uncertainties pose the major limitation of this work. In 
particular, the probability of having coinfection with SARS-CoV-2 when in fact the symptoms are 
caused by another pathogen is crucial to the inference that can be made from a positive SARS-CoV-2 
test and should be investigated in future studies.  
We now briefly turn to the third epistemological question that we posed in the beginning, but so far 
have neglected: Given a positive test result, what should we do? We can conclude that unless one is 
certain that the test has a high specificity, clinical decision making should not be based solely on such 
tests. To test specificity, Wernike et al. (2020) recommended to pre-test each batch of PCR reagents 
at least 50 times with negative control samples. Furthermore, given that COVID-19 might show a 
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seasonality similar to other human coronaviruses (Olofsson et al. 2011; Nickbakhsh et al. 2019; 
Monto et al. 2020) and that similar symptoms might be caused by certain bacteria (Lin et al. 2020), 
the possibility of other viral or bacterial infections should always be considered. That this approach is 
feasible has been shown by initial studies (Jian et al. 2020; Kim et al. 2020; Lin et al. 2020; Nowak et 
al. 2020). In general, policy makers and the media should recognize the limitations of the new SARS-
CoV-2 tests and consider the possibility that deceased patients who were tested positive for this virus 
might only have died with but not because of it. 
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Figures 
 
Fig. 1: Left: Posterior probability for the hypothesis V (“The tested patient is infected with the SARS-
CoV-2”) as a function of the prior probability or base rate P(V) plotted on a log scale. Right: Evidence 
measured by the likelihood ratio as a function of the test sensitivity with specificity fixed at 0.95 or 
0.9, respectively. The black straight line denotes the threshold of a likelihood of 8 above which we 
speak of strong evidence for the hypothesis V. 
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Fig. 2: Bayesian network model of the relationship between a positive test T and hypothesis C. 
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Fig. 3: Confirmation of the hypothesis C (that SARS-CoV-2 caused the COVID-19-like symptoms of a 
patient) by a positive test as a function of the prior probability for C, q≡P(V|¬C) and different test 
performances. 
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Fig. 4: Evidence for the hypothesis C against ¬C given by 1/x (Equation 15). The evidence is plotted as 
a function of the test sensitivity for fixed specificity of 80% and 95%, respectively, and different 
values of q, the probability that a patient who has symptoms caused by a pathogen other than SARS-
CoV-2 additionally has SARS-CoV-2 coinfection. The black solid line denotes the threshold of strong 
evidence (1/x=8). 
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Fig. 5: (Dis-)confirmation of C and evidence of ¬C against C (Equation 19) constituted by a positive 
influenza A test in dependence of p’, the probability of having an influenza A infection when in fact 
the symptoms are caused by SARS-CoV-2. 
 
